GSA Capital Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

GSA Capital Partners’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,769	Closed	-$529K	–	2041
2022 Q3	$529K	Buy	+7,769	New	+$428K	0.07%	530
2022 Q1	–	Sell	-49,327	Closed	-$1.44M	–	1967
2021 Q4	$1.44M	Sell	49,327 -17,075	-26%	-$529K	0.18%	83
2021 Q3	$1.69M	Buy	66,402 +59,830	+910%	+$1.76M	0.17%	102
2021 Q2	$230K	Buy	+6,572	New	+$257K	0.03%	1116
2019 Q4	–	Sell	-5,756	Closed	-$279K	–	1830
2019 Q3	$279K	Buy	+5,756	New	+$300K	0.04%	961
2019 Q2	–	Sell	-4,298	Closed	-$227K	–	1829
2019 Q1	$227K	Buy	+4,298	New	+$211K	0.02%	1164
2016 Q3	–	Sell	-10,900	Closed	-$181K	–	2036
2016 Q2	$181K	Buy	+10,900	New	+$220K	0.01%	1596

Other funds holding GBT

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

GSA Capital Partners's GBT Position: Q4 2022 in Review

GSA Capital Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 7,769 shares — an estimated $529K sold.

GSA Capital Partners first reported a position in GBT in Q2 2016 and held it in 7 quarters. The position peaked at $1.69M in Q3 2021. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

GSA Capital Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 7,769 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $529K.
GSA Capital Partners first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
GSA Capital Partners's Global Blood Therapeutics, Inc. position peaked at $1.69M in Q3 2021.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.